Literature DB >> 31364899

Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy.

Camilla H Stokkevåg1,2, Daniel J Indelicato3, Klaus Herfarth4, Henriette Magelssen5, Morten E Evensen6, Maren Ugland1, Terje Nordberg1, Tove A Nystad6, Camilla Hægeland6, Mirjam D Alsaker7, Kjetil Ulven7, Jon E Dale1, Grete M Engeseth1, Camilla G Boer1, Laura Toussaint8, Josefine S Kornerup7, Helge E S Pettersen1, Marianne Brydøy1, Petter Brandal5, Ludvig P Muren8.   

Abstract

Background: Children with brain tumors undergoing radiotherapy are at particular risk of radiation-induced morbidity and are therefore routinely considered for proton therapy (PT) to reduce the dose to healthy tissues. The aim of this study was to apply pediatric constraints and normal tissue complication probability (NTCP) models when evaluating the differences between PT and contemporary photon-based radiotherapy, volumetric modulated arc therapy (VMAT).
Methods: Forty patients (aged 1-17 years) referred from Norwegian institutions to cranial PT abroad during 2014-2016 were selected for VMAT re-planning using the original CT sets and target volumes. The VMAT and delivered PT plans were compared by dose/volume metrics and NTCP models related to growth hormone deficiency, auditory toxicity, visual impairment, xerostomia, neurocognitive outcome and secondary brain and parotid gland cancers.
Results: The supratentorial brain, temporal lobes, hippocampi, hypothalamus, pituitary glands, cochleas, salivary glands, optic nerves and chiasm received lower mean doses from PT. Reductions in population median NTCP were significant for auditory toxicity (VMAT: 3.8%; PT: 0.3%), neurocognitive outcome (VMAT: 3.0 IQ points decline at 5 years post RT; PT: 2.5 IQ points), xerostomia (VMAT: 2.0%; PT: 0.6%), excess absolute risk of secondary cancer of the brain (VMAT: 9.2%; PT: 6.7%) and salivary glands (VMAT: 2.8%; PT:0.5%). Across all patients, 23/38 PT plans had better or comparable estimated risks for all endpoints (within ±10% of the risk relative to VMAT), whereas for 1/38 patients all estimates were better or comparable with VMAT. Conclusions: PT reduced the volumes of normal tissues exposed to radiation, particularly low-to-intermediate dose levels, and this was reflected in lower NTCP. Of the included endpoints, substantial reductions in population medians were seen from the delivered PT plans for auditory complications, xerostomia, and risk of secondary cancers of the brain and salivary glands.

Entities:  

Mesh:

Year:  2019        PMID: 31364899     DOI: 10.1080/0284186X.2019.1643496

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

1.  Neurocognitive impairment following proton therapy for paediatric brain tumour: a systematic review of post-therapy assessments.

Authors:  Noorazrul Yahya; Hanani Abdul Manan
Journal:  Support Care Cancer       Date:  2020-10-11       Impact factor: 3.603

2.  Dosimetric analysis and biological evaluation between proton radiotherapy and photon radiotherapy for the long target of total esophageal squamous cell carcinoma.

Authors:  Yongbin Cui; Yuteng Pan; Zhenjiang Li; Qiang Wu; Jingmin Zou; Dali Han; Yong Yin; Changsheng Ma
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

3.  Influence of Target Location, Size, and Patient Age on Normal Tissue Sparing- Proton and Photon Therapy in Paediatric Brain Tumour Patient-Specific Approach.

Authors:  Mikaela Dell'Oro; Michala Short; Puthenparampil Wilson; Chia-Ho Hua; Melissa Gargone; Thomas E Merchant; Eva Bezak
Journal:  Cancers (Basel)       Date:  2020-09-10       Impact factor: 6.639

Review 4.  A scoping review of patient selection methods for proton therapy.

Authors:  Nicole Zientara; Eileen Giles; Hien Le; Michala Short
Journal:  J Med Radiat Sci       Date:  2021-09-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.